4//SEC Filing
Vivo Capital VIII, LLC 4
Accession 0001567619-21-002591
CIK 0001831363other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 3:08 PM ET
Size
28.6 KB
Accession
0001567619-21-002591
Insider Transaction Report
Form 4
Vivo Capital VIII, LLC
10% Owner
Transactions
- Conversion
Common Stock
2021-02-09+1,933,185→ 1,933,185 total(indirect: Vivo Capital Fund VIII, L.P.) - Purchase
Common Stock
2021-02-09$17.00/sh+14,275$242,675→ 281,223 total(indirect: Vivo Capital Surplus Fund VIII, L.P.) - Conversion
Series B Preferred Stock
2021-02-09−713,203→ 0 total(indirect: Vivo Capital Fund VIII, L.P.)→ Common Stock (1,569,047 underlying) - Conversion
Common Stock
2021-02-09+266,948→ 266,948 total(indirect: Vivo Capital Surplus Fund VIII, L.P.) - Purchase
Common Stock
2021-02-09$17.00/sh+103,372$1,757,324→ 2,036,557 total(indirect: Vivo Capital Fund VIII, L.P.) - Purchase
Common Stock
2021-02-09$17.00/sh+357,353$6,075,001→ 357,353 total(indirect: Vivo Opportunity Fund, L.P.) - Conversion
Series B Preferred Stock
2021-02-09−98,484→ 0 total(indirect: Vivo Capital Surplus Fund VIII, L.P.)→ Common Stock (216,666 underlying) - Conversion
Series C Preferred Stock
2021-02-09−50,282→ 0 total(indirect: Vivo Capital Surplus Fund VIII, L.P.)→ Common Stock (50,282 underlying) - Conversion
Series C Preferred Stock
2021-02-09−364,138→ 0 total(indirect: Vivo Capital Fund VIII, L.P.)→ Common Stock (364,138 underlying)
Footnotes (4)
- [F1]Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F2]Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F3]Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F4]Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Documents
Issuer
Terns Pharmaceuticals, Inc.
CIK 0001831363
Entity typeother
Related Parties
1- filerCIK 0001618789
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 3:08 PM ET
- Size
- 28.6 KB